Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
Mallinckrodt
AstraZeneca
Merck
Moodys

Last Updated: November 15, 2019

DrugPatentWatch Database Preview

METHYLIN Drug Profile

See Plans and Pricing

« Back to Dashboard

When do Methylin patents expire, and when can generic versions of Methylin launch?

Methylin is a drug marketed by Specgx Llc and is included in three NDAs. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has ten patent family members in nine countries.

The generic ingredient in METHYLIN is methylphenidate hydrochloride. There are thirty-two drug master file entries for this compound. Forty-two suppliers are listed for this compound. Additional details are available on the methylphenidate hydrochloride profile page.

Drug patent expirations by year for METHYLIN
Drug Prices for METHYLIN

See drug prices for METHYLIN

Drug Sales Revenue Trends for METHYLIN

See drug sales revenues for METHYLIN

Recent Clinical Trials for METHYLIN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Nicoleta StoiceaPhase 1

See all METHYLIN clinical trials

Recent Litigation for METHYLIN

Identify potential future generic entrants

District Court Litigation
Case NameDate
Tris Pharma Inc. v. Actavis Laboratories FL Inc.2014-10-15

See all METHYLIN litigation

Pharmacology for METHYLIN
Synonyms for METHYLIN
.alpha.-Phenyl-2-piperidineacetic acid methyl ester
113-45-1
2-Piperidineacetic acid, .alpha.-phenyl-, methyl ester
2-Piperidineacetic acid, alpha-phenyl-, methyl ester
298-59-9 (hydrochloride)
4311/B Ciba
AB01563134_01
AC1L1HJM
AKOS022506757
alpha-Phenyl-2-piperidineacetic acid methyl ester
alpha-Phenyl-alpha-(2-piperidyl)acetic acid methyl ester
API0008866
BCP18286
BDBM50062912
BRD-A19585813-003-01-7
C 4311
C07196
Calocain
Centedein
Centedein (Salt/Mix)
Centedrin (Salt/Mix)
Centedrine (Salt/Mix)
Centredin
CHEBI:84276
CHEMBL796
Concerta
Concerta, Methylin, Ritalin
Cotempla XR-ODT
CS-4657
d-methylphenidate HCl
D04999
Daytrana
Daytrana (TN)
DB00422
DEA No. 1724
DTXSID5023299
DUGOZIWVEXMGBE-UHFFFAOYSA-N
EINECS 204-028-6
FT-0700534
GTPL7236
HSDB 3126
HY-B1091
Jornay PM (a.k.a. HLD200)
L001307
LS-565
Meridil
Metadate
Metadate ER
Methyl .alpha.-phenyl-.alpha.-(2-piperidyl)acetate
Methyl .alpha.-phenyl-.alpha.-2-piperidinylacetate
Methyl .alpha.-phenyl-2-piperidine-acetate
Methyl .alpha.-phenyl-2-piperidineacetate
Methyl (2-phenyl-2-(2-piperidyl)acetate)
Methyl 2-phenyl-2-(piperidin-2-yl)acetate
methyl 2-phenyl-2-piperidin-2-ylacetate
Methyl alpha-phenyl-alpha-(2-piperidyl)acetate
Methyl alpha-phenyl-alpha-2-piperidinylacetate
methyl alpha-piperid-2-ylphenylacetate
Methyl phenidate
Methyl phenidyl acetate
Methyl phenidylacetate
Methyl phenyl(2-piperidinyl)acetate #
methyl phenyl(piperidin-2-yl)acetate
Methylfenidan
Methylin (Salt/Mix)
Methylin ER
Methylofenidan
Methylphen
Methylphenidan
methylphenidate
METHYLPHENIDATE (SEE ALSO: METHYLPHENIDATE HYDROCHLORIDE, CAS 298-59-9, NTPNO 10266-R)
Methylphenidate (USAN/INN)
Methylphenidate [INN:BAN]
Methylphenidate [USAN:INN:BAN]
Methylphenidate HCl
Methylphenidatum
Methylphenidatum [INN-Latin]
Methylphenidylacetate hydrochloride
MethyPatch
Metilfenidato
Metilfenidato [INN-Spanish]
Metilfenidato [Italian]
NCGC00248587-01
NCI-C56280
Phenidylate
phenyl-piperidin-2-yl-acetic acid methyl ester
Plimasine
PMS-Methylphenidate
Riphenidate
Ritalin
Ritalin (Salt/Mix)
Ritalin LA
Ritaline
Ritaline (Salt/Mix)
Ritcher works
Rubifen
SBI-0206868.P001
SCHEMBL37178
Tsentedrin
Paragraph IV (Patent) Challenges for METHYLIN
Tradename Dosage Ingredient NDA Submissiondate
METHYLIN SOLUTION;ORAL methylphenidate hydrochloride 021419 2010-04-13

US Patents and Regulatory Information for METHYLIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Specgx Llc METHYLIN methylphenidate hydrochloride SOLUTION;ORAL 021419-001 Dec 19, 2002 AA RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Specgx Llc METHYLIN ER methylphenidate hydrochloride TABLET, EXTENDED RELEASE;ORAL 075629-002 May 9, 2000 AB RX No No   Start Trial   Start Trial   Start Trial
Specgx Llc METHYLIN methylphenidate hydrochloride TABLET, CHEWABLE;ORAL 021475-002 Apr 15, 2003 DISCN Yes No   Start Trial   Start Trial   Start Trial
Specgx Llc METHYLIN methylphenidate hydrochloride SOLUTION;ORAL 021419-002 Dec 19, 2002 AA RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Specgx Llc METHYLIN methylphenidate hydrochloride TABLET, CHEWABLE;ORAL 021475-001 Apr 15, 2003 DISCN Yes No   Start Trial   Start Trial   Start Trial
Specgx Llc METHYLIN ER methylphenidate hydrochloride TABLET, EXTENDED RELEASE;ORAL 075629-001 May 9, 2000 AB RX No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
AstraZeneca
Merck
Baxter
McKesson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.